TargAnox Raises Series A

TargAnox, a Boston-based drug startup focused on oxidative stress, has raised $5.1 million in Series A funding, according to Xconomy. Ascent Biomedical Ventures led the round, and was joined by Partners Innovation Fund.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.